The name of the article is called Osteoporosis. This article was updated by Zieve, David; Juhn, Greg; Eltz, David, R. (A.D.A.M. editorial team). This article was initially reviewed by Eckman, Ari, S. of John Hopkins School of Medicine on 23 November 2009. This article is available at the U.S. National Library of Medicine of National Institute of Health (NIH). This article describes Osteoporosis which is a condition associated with postmenopausal women; women above age 50. This category of women is susceptible to fractures of the vertebra, hip and wrist. Osteoporosis is essentially a product of calcium and phosphate homeostasis.
The guideline title is called Osteoporosis. The guideline was derived from the American college of Obstetricians and Gynecology (ACOG). Osteoporosis. Washington (DC): American college of obstetrician and Gynecologists (ACOG); 2004 Jan. 14 p. the aim of the guideline was to support practitioners in decision making concerning gynecology and obstetrics health care. Another objective of the guideline is to evaluate the right screening approaches and useful pharmacological interventions used in prevention and treatment of osteoporosis. The guideline focuses on adult women for the purpose of screening and guidance. The other persons targeted by this guideline are the postmenopausal women who are vulnerable to osteoporosis, for the purpose of treatment and prevention. According to the guideline osteoporosis is associated with hormone malfunction particularly that occurs in post menopause women. Thus, this condition can be alleviated using hormone therapies. However, hormone therapies are associated with numerous side effects including bone recession.
The name of the clinical trial is called Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome. The trial was carried out at the university of Maryland Amish Research clinic. The condition for which the clinical trial was performed was Osteoporosis Pseudoglioma for which the drug of intervention was lithium. The trial was verified by University of Maryland on April 2010 when the study was not yet ready for the recruitment of the subjects. This trial was funded by University of Maryland and was denoted identity number NCT01108068. The trial was targeted to treat a maximum of 10 cases of OPPG using lithium. The persons eligible for this study are persons between ages 4 to 64 who may be of any gender and who are victim of osteoporosis-pseudoglioma (OPPG). However, the trial accepts healthy volunteers who are first degree relative to a victim of the condition. Also the subjects should not have contraindication to lithium carbonate. Pregnant women and women who are unwilling to undergo pregnancy test are not accepted. Again, the individual should not have the Glomerular filtration rate lower that 80 cc/min. This study seeks to overcome the inadequacy experienced with using bisphosphonates drugs such as alendronate and pamidronate in treatment of osteoporosis-pseudoglioma. These drugs cannot prevent fracture of the hip. Lithium has been hypothesized to give more desirable outcome in treatment of OPPG as was evident from mouse model outcome.